On this page
This entry or formulation may be investigational and may not correspond to an FDA-approved product; safety and efficacy may not have been established. Kairo lists it for identification and record-keeping only.
Overview
Product & regulatory status
Research entry: inclusion is for identification, not approval or a recommendation to use it. Verify the exact product and current US status with a pharmacist.
Growth-hormone signaling
The long-acting analog stimulates growth-hormone-releasing hormone signaling, with downstream increases in GH and IGF-1 in the cited trials. A change in these blood markers is different from a proven improvement in how someone feels or functions. [1]
What the evidence shows
Hormone measurements
Two short placebo-controlled trials in healthy adults found increases in GH and IGF-1 with long-acting CJC-1295. Hormone changes do not establish better sleep, injury healing, or long-term health. [1]
Participants and follow-up
The early placebo-controlled studies involved healthy adults and lasted 28 or 49 days. They measured hormone responses and pharmacokinetics. They were not designed to establish long-term disease prevention, strength gains, or improvement in sleep quality. [1]
What remains unknown
Long-term safety and benefits outside the measured trial outcomes remain uncertain.
Safety
Reported safety concerns
FDA reports increased heart rate and systemic vasodilatory reactions associated with CJC-1295. [2]
Long-acting identity
The trial describes a long-acting study compound. A product with a similar name, different peptide identity, or added ingredient cannot inherit its pharmacokinetics or preparation instructions. [1]
Understanding product quality
Compounded drugs are not FDA-approved finished products. Poor preparation can cause contamination or incorrect strength. A catalog entry or a research paper is not a quality assessment of your product. [3]
When to seek urgent help
Severe allergic symptoms such as trouble breathing, throat or tongue swelling, or fainting need immediate help. Call 911 or your local emergency number. This is general emergency information, not a complete list of risks for this compound. [4]
A starting point for discussion
This is not a complete list of adverse effects or interactions. Your health history, other medicines, and the exact formulation matter. Missing safety data is not evidence of safety.
Common questions
What does DAC change?
The long-acting compound studied in these trials differs from products sold as “no DAC.” Do not reuse its evidence or half-life for a different molecule.
Questions for your clinician
Does the evidence match my condition and this exact product? What risks or interactions matter for me? How would we assess whether it is helping?
Sources
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults2006 · randomized human trials · PMID 16352683
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety RisksFDA · safety information · accessed September 2026
- Compounding and the FDA: Questions and AnswersFDA · product quality and regulation
- AnaphylaxisMedlinePlus · recognizing an emergency
Educational information, not a recommendation to use a compound. Kairo does not give dosing advice. Review decisions with a licensed healthcare professional.